PMID- 34842960
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20231213
IS  - 1432-069X (Electronic)
IS  - 0340-3696 (Linking)
VI  - 314
IP  - 9
DP  - 2022 Nov
TI  - Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) 
      therapy for malignant melanoma.
PG  - 887-895
LID - 10.1007/s00403-021-02305-z [doi]
AB  - Anti-programmed cell death protein 1 (PD-1) antibody drugs, nivolumab and 
      pembrolizumab, are regarded as first-line therapies for advanced malignant 
      melanoma. Anti-PD-1 therapy suppresses tumor immunity, and the therapeutic effect 
      is frequently correlated with the number of tumor-infiltrating lymphocytes (TIL) 
      and tumor mutation burden (TMB). However, sampling tumor tissues from the 
      metastatic sites to examine the number of TILs and TMB level is often 
      challenging. Herein, we focused on chemokines in blood to determine whether they 
      can predict the therapeutic effect of anti-PD-1 (nivolumab) therapy. First, we 
      measured 44 types of chemokines and cytokines in the blood of 8 advanced 
      malignant melanomas before anti-PD-1 (nivolumab) treatment and examined the 
      relationship between the levels of these proteins and therapeutic effect of the 
      drug treatment, which suggested that C-C motif chemokine 5 (CCL5) and C-X-C motif 
      chemokine ligand 12 (CXCL12) were candidates for biomarkers to predict the 
      therapeutic effect of anti-PD-1 therapy. Next, we measured the blood levels of 
      CCL5 and CXCL12 in 22 patients with advanced malignant melanomas before the 
      administration of anti-PD-1 antibody. We evaluated tumor infiltration of 
      CD8-positive T cells by immunostaining in nine patients in whom the metastatic 
      site could be sampled at the beginning of the treatment. The patients with lower 
      than average levels of CCL5 and CXCL12 had a large number of TILs (P = 0.04) and 
      good disease-specific survival rate (P = 0.04). Therefore, CCL5 and CXCL12 could 
      likely be used as biomarkers to predict the therapeutic effect of anti-PD-1 
      (nivolumab) therapy.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Nakamura, Kenta
AU  - Nakamura K
AUID- ORCID: 0000-0003-1350-0365
AD  - Department of Dermatology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan. kenta1983@shinshu-u.ac.jp.
FAU - Ashida, Atsuko
AU  - Ashida A
AD  - Department of Dermatology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan.
FAU - Kiniwa, Yukiko
AU  - Kiniwa Y
AD  - Department of Dermatology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan.
FAU - Okuyama, Ryuhei
AU  - Okuyama R
AD  - Department of Dermatology, Shinshu University School of Medicine, 3-1-1 Asahi, 
      Matsumoto, Nagano, 390-8621, Japan.
LA  - eng
PT  - Journal Article
DEP - 20211129
PL  - Germany
TA  - Arch Dermatol Res
JT  - Archives of dermatological research
JID - 8000462
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Ligands)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Chemokine CCL5/therapeutic use
MH  - Humans
MH  - Ligands
MH  - *Melanoma/drug therapy/pathology
MH  - *Nivolumab/therapeutic use
MH  - Skin Neoplasms
MH  - Melanoma, Cutaneous Malignant
OTO - NOTNLM
OT  - Chemokine
OT  - C-C motif chemokine 5
OT  - C-X-C motif chemokine ligand 12
OT  - Melanoma
OT  - PD-1
EDAT- 2021/11/30 06:00
MHDA- 2022/09/28 06:00
CRDT- 2021/11/29 12:41
PHST- 2020/08/26 00:00 [received]
PHST- 2021/11/16 00:00 [accepted]
PHST- 2021/11/13 00:00 [revised]
PHST- 2021/11/30 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2021/11/29 12:41 [entrez]
AID - 10.1007/s00403-021-02305-z [pii]
AID - 10.1007/s00403-021-02305-z [doi]
PST - ppublish
SO  - Arch Dermatol Res. 2022 Nov;314(9):887-895. doi: 10.1007/s00403-021-02305-z. Epub 
      2021 Nov 29.